By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



  Busan    Korea
Phone: n/a Fax: n/a



Company News
ASCO2016: SillaJen Announces Poster Presentation At ASCO Annual Meeting 5/31/2016 9:24:27 AM
SillaJen Announces Commercial Manufacturing Agreement With ABL Europe For Lead Oncolytic Virus, Pexa-Vec 5/16/2016 7:34:10 AM
SillaJen Enrolls First U.S. Patient In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer 3/29/2016 7:26:38 AM
Medivate Partners Invests $12 Million In SillaJen 3/21/2016 6:24:54 AM
SillaJen Announces First Patient Randomized In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer 1/6/2016 6:54:16 AM
TRANSGENE (ENX:TNG) And SillaJen Announce Revised Agreement For Pexa-Vec Oncolytic Viral Therapy And Provide Update On Clinical Development 11/12/2015 12:23:04 PM
SillaJen Publishes Clinical Data Demonstrating Safe Administration Of Multiple Intravenous Doses Of Oncolytic Virus In Patients With Metastatic Colorectal Cancer 6/29/2015 6:40:16 AM
SillaJen Presents Data Demonstrating Pexa-Vec Synergy With Angiogenesis Inhibitors: A Collaboration With University of California, San Francisco (UCSF) 4/20/2015 1:27:30 PM
SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015 11:02:56 AM
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014 10:41:01 AM